All In Biotech

Drug Trial Radar · NCT06328725

Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular Dystrophy

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Trial to Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular Dystrophy

Last checked: Nov 20, 2026Latest source record: Mar 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

88

Planned (sponsor's estimate)

Start

Mar 2024

Primary completion

Nov 2025

Study completion Nov 2025

Sponsor

Lead sponsor
ENCellIndustry
Sponsor type
Industry
First posted
Mar 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 6 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Trial to Evaluate the Efficacy and Safety of EN001 in Patients with Duchenne Muscular Dystrophy

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • EN001Drug

    Phase 1 * Cohort 1: EN001 5.0x10\^5 cells/kg administered intravenously (IV) 3 times at 6 week intervals. * Cohort 2: EN001 2.5x10\^6 cells/kg administered intravenously (IV) 3 times at 6 week intervals. Phase 2 * Experimental Group: The recommended phase 2 dose (RP2D) of EN001 is administered intravenously (IV) three times at six-week intervals. * Control Group: EN001 placebo is administered intravenously (IV) three times at six-week intervals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. <Phase 1> Adverse drug reactions related to dose limiting toxicity (DLT)Time frame: Up to 14 weeks
  2. <Phase 1> Adverse drug reactions related to discontinuation of clinical trial drug administrationTime frame: Up to 14 weeks
  3. <Phase 2> Change in time to stand test (TTSTAND)Time frame: At 48 weeks compared to baseline (Visit 2)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.